Definition of a small core transcriptional circuit regulated by AML1-ETO

Stengel, Kristy R.; Ellis, Jacob; Spielman, Clare; Bomber, Monica; Hiebert, Scott W.

doi:10.1016/j.molcel.2020.12.005

Cited by 58 publications

(46 citation statements)

References 75 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Core binding factors are necessary in normal hematopoiesis. Translocation events alter the normal DNA binding of the heterodimer and create alternate binding, leading to disruption of the normal transcription program and resulting in maturation arrest [ 12 ]. For example, the fusion protein AML/ETO negatively impacts the myeloid differentiation promoting transcriptional effect of PU1 by binding and displacing the coactivator c-Jun from PU1 [ 13 ].…”

Section: Pathogenesismentioning

confidence: 99%

Core binding factor acute myelogenous leukemia-2021 treatment algorithm

Borthakur

Kantarjian

2021

Blood Cancer J.

View full text Add to dashboard Cite

Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective implementation of available therapeutic measures and appropriate disease monitoring. The incorporation of gemtuzumab ozogamicin into frontline therapy should be standard. Cytarabine based induction/consolidation regimen may be combined with anthracycline (3 + 7 standard) or antimetabolite, fludarabine. Serial quantitative polymerase chain reaction (QPCR) monitoring of unique fusion transcripts allows monitoring for measurable residual disease clearance; this allows for better prognostication and well as treatment modifications.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Core binding factor acute myelogenous leukemia-2021 treatment algorithm

Borthakur

Kantarjian

2021

Blood Cancer J.

View full text Add to dashboard Cite

show abstract

“…Images show bedGraph files produced with HOMER loaded into IGV for visualization. Figure parts reprinted with permission from ( Stengel et al, 2021 ). Select genes or eRNA that are significantly changed in at least 2 time points ( Figure 6 B).…”

Section: Step-by-step Methods Detailsmentioning

confidence: 99%

“…Images show bedGraph files produced with HOMER loaded into IGV for visualization. Figure parts reprinted with permission from ( Stengel et al, 2021 ).…”

Section: Step-by-step Methods Detailsmentioning

confidence: 99%

“…This protocol combines rapid degradation of endogenous transcription factors with nascent transcript analysis to define the earliest, and likely direct, regulatory targets of transcription factors. For complete details on the use and execution of this protocol, please refer to Stengel et al, 2021 ).…”

mentioning

confidence: 99%

“…For complete details on the use and execution of this protocol, please refer to Stengel et al, 2021 ).…”

mentioning

confidence: 99%

See 2 more Smart Citations

A protocol for rapid degradation of endogenous transcription factors in mammalian cells and identification of direct regulatory targets

et al. 2021

Self Cite

View full text Add to dashboard Cite

Summary Transcriptional changes happen within minutes; however, RNAi or genetic deletion requires days to weeks before transcription networks can be analyzed. This limitation has made it challenging to distinguish direct from indirect targets of sequence-specific transcription factors. This inability to define direct transcriptional targets hinders detailed studies of transcriptional mechanisms. This protocol combines rapid degradation of endogenous transcription factors with nascent transcript analysis to define the earliest, and likely direct, regulatory targets of transcription factors. For complete details on the use and execution of this protocol, please refer to Stengel et al., 2021 ).

show abstract